EUVIMEDEUVIMED entdecken
Multizentrische Studie

Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

Marta Araujo-Castro iD, Betina Biagetti, Edelmiro Menéndez Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual-Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich Hualpa, Rogelio García-Centeno, Laura González-Fernández und 35 weitere

Endocrine-Related Cancer · 2024

DOI: 10.1530/erc-24-0043 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Marta Araujo-Castro und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (…. Hauptthemen laut MEDLINE: Somatostatin, Human Growth Hormone, Prolactin, Neuroendocrine Tumors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and/or pegvisomant. Patients were classified in two groups: GH&PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs . All GH&PRL-Pit-NET cases treated with pasireotide ( n = 6) and 82.6% ( n = 19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&PRL-Pit-NETs (84.9% vs 66.7%, P = 0.178). We conclude that despite the more aggressive behavior of GH&PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SomatostatinHuman Growth HormoneProlactinNeuroendocrine TumorsAcromegalyHumansMaleFemaleMiddle AgedAdultRetrospective StudiesPituitary NeoplasmsAgedYoung Adult

Stichwörter der Autor:innen

acromegalypasireotidepegvisomantpituitary neuroendocrine tumorsprolactin

Substanzen

pasireotidepegvisomantSomatostatinHuman Growth HormoneProlactin

Autor:innen und Institutionen

  • Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain.
  • Department of Endocrinology and Nutrition, Hospital Universitario Vall de Hebrón, CIBERER U747 (ISCIII), ENDO-ERN, Barcelona, Spain.
  • Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias & Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Asturias, Spain.
  • Department of Endocrinology and Nutrition, Hospital Universitario de A Coruña, A Coruña, Spain.
  • Department of Neurosurgery, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Department of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Cataluña L'Hospitalet de Llobregat, Spain.

ORCID-Profile: Marta Araujo-Castro, María Calatayud, Cristina Alvarez-Escola, Pedro Iglesias, Cristina Lamas, Miguel Sampedro-Núñez, Manel Puig-Domingo

Zitieren

APA

Araujo-Castro, M., Biagetti, B., Menéndez Torre, E., Novoa-Testa, I., Cordido, F., Pascual-Corrales, E., Rodríguez Berrocal, V., Guerrero-Pérez, F., Vicente, A., Percovich Hualpa, J. C., García-Centeno, R., González-Fernández, L., Ollero García, M. D., Irigaray Echarri, A., Moure Rodríguez, M. D., Novo-Rodríguez, C., Calatayud, M., Villar-Taibo, R., Bernabéu, I., …, & Puig-Domingo, M. (2024). Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0043

Vancouver

Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E, et al. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocrine-Related Cancer. 2024. doi:10.1530/erc-24-0043

BibTeX
@article{AraujoCastro2024,
  author = {Araujo-Castro, Marta and Biagetti, Betina and Menéndez Torre, Edelmiro and Novoa-Testa, Iría and Cordido, Fernando and Pascual-Corrales, Eider and Rodríguez Berrocal, Víctor and Guerrero-Pérez, Fernando and Vicente, Almudena and Percovich Hualpa, Juan Carlos and García-Centeno, Rogelio and González-Fernández, Laura and Ollero García, María Dolores and Irigaray Echarri, Ana and Moure Rodríguez, María Dolores and Novo-Rodríguez, Cristina and Calatayud, María and Villar-Taibo, Rocío and Bernabéu, Ignacio and Alvarez-Escola, Cristina and Benítez Valderrama, Pamela and Tenorio-Jiménez, Carmen and Abellán Galiana, Pablo and Venegas, Eva and González-Molero, Inmaculada and Iglesias, Pedro and Blanco-Carrera, Concepción and Vidal-Ostos De Lara, Fernando and de Miguel Novoa, Paz and López Mezquita, Elena and Hanzu, Felicia Alexandra and Aldecoa, Iban and Aznar, Silvia and Lamas, Cristina and Aulinas, Anna and Asla, Queralt and Gracia Gimeno, Paola and Recio-Córdova, José María and Avilés-Pérez, María Dolores and Asensio-Wandosell, Diego and Sampedro-Núñez, Miguel and Cámara, Rosa and Paja Fano, Miguel and Ruz-Caracuel, Ignacio and Fajardo, Carmen and Marazuela, Mónica and Puig-Domingo, Manel},
  title = {Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs},
  journal = {Endocrine-Related Cancer},
  year = {2024},
  doi = {10.1530/erc-24-0043}
}
Kostenlos starten →